TransCode says Phase 1a trial shows 71.4% stable disease rate for TTX-MC138 in advanced solid tumors
Bitget2026/09/28 12:06- TransCode Therapeutics released updated follow-up results from its ongoing Phase 1a trial of TTX-MC138 in advanced solid tumors.
- Results have already been presented as an updated data cut, showing many patients achieved disease stabilization, with some remaining progression-free for a year.
- Safety profile remained acceptable across tested doses, supporting continued development without new tolerability signals.
- Exploratory biomarker work pointed to treatment-linked immune activation, reinforcing the clinical signal.
- Management is evaluating dose-expansion plans to confirm activity in selected cancers and molecularly defined patient groups.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
